Share on LinkedInShare on LinkedIn

ARTICLE · 11 MAY 2020

COVID-19 Medicines Receive Australian Therapeutic Goods Administration Exemption

Special measures have been passed in Australia which exempt specified treatments for COVID-19 from requirements to be registered on the Australian Register of Therapeutic Goods (ARTG) prior to their supply.

AustraliaCoronavirus (COVID-19)

Note: Nothing in our article is to be taken as providing medical advice or recommending or endorsing the use of the drugs mentioned below for any purpose.

Special measures have been passed in Australia which exempt specified treatments for COVID-19 from requirements to be registered on the Australian Register of Therapeutic Goods (ARTG) prior to their supply. 

Generally speaking (and subject to a number of special arrangements), registration of pharmaceuticals, medical devices and other therapeutic goods on the ARTG is a pre-requisite to the lawful supply of those registered goods in Australia for the indications specified in the ARTG listing.  ARTG registration follows a rigorous assessment of the goods by the Therapeutic Goods Administration.  For a drug to be approved and registered, data demonstrating the safety and efficacy of that drug for a particular condition or disease is required, and that data is typically obtained by carrying out phase 3 (large-scale)

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from